Washington, District of Columbia, United States
I work at the intersection of science, policy, and regulation to help bring better cancer treatments to patients. With over a decade of experience in oncology drug development and regulatory science, I’ve had the opportunity to collaborate with FDA, industry, academia, and patient advocates on projects that shape how clinical trials are designed and how new therapies reach people faster. My focus has been on creating practical solutions, whether that’s advancing novel endpoints like ctDNA, improving the use of real-world evidence in regulatory decision-making, or harmonizing diagnostic development. I’ve also been part of efforts to evaluate AI-driven tools and optimize trial designs in rare cancers, always with the goal of making drug development more efficient and reliable, while keeping patients at the center of regulatory science and ensuring innovation translates into meaningful outcomes in cancer care.